Raymond James Ltd. facilitates $30 million equity financing for Medexus Pharmaceuticals  Inc.

Goodmans LLP acted for Raymond James Ltd., as lead underwriter and sole bookrunner, in connection with the $30 million equity financing of Medexus Pharmaceuticals Inc. by way of shelf prospectus offering.

The overnight marketed underwritten offering comprised of 7,500,000 common shares of Medexus at a public offering price of $4.00 per common share. Medexus expects that the net proceeds of the offering will be used: (i) to repay a US$2.5 million credit received from medac in September 2021 and pay a portion of the milestone payment amount to medac, and (ii) for working capital and general corporate purposes, which may include funding the company's ongoing business development activities and initiatives.

Medexus is a leading specialty pharmaceutical company with a strong North American commercial platform and a growing portfolio of innovative and rare disease treatment solutions.